Status:
COMPLETED
Trial of Aripiprazole in the Treatment of CD in Adolescents
Lead Sponsor:
University of Iowa
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Conduct Disorder
Eligibility:
MALE
13-17 years
Phase:
PHASE4
Brief Summary
The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder. The in...
Detailed Description
The use of atypical antipsychotics in children began in 1992 with several small case series with clozapine. Since that time, five other atypical agents, risperidone, olanzapine, quetiapine, ziprasidon...
Eligibility Criteria
Inclusion
- Male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder.
Exclusion
- Clinically significant laboratory and/or ECG abnormalities
- Pre-existing health conditions that would compromise patient safety
- Mental retardation
- Previous use of aripiprazole
- Active psychosis
Key Trial Info
Start Date :
November 17 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 23 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00250705
Start Date
November 17 2004
End Date
March 23 2009
Last Update
July 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242